Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. First case of cystic fibrosis in Greenland - diagnosed by neonatal screening

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: Not just hot air

    Research output: Contribution to journalReviewpeer-review

View graph of relations

BACKGROUND: Pseudomonas aeruginosa is difficult to eradicate from the lungs of cystic fibrosis (CF) patients due to biofilm formation. Organs and blood are independent pharmacokinetic (PK) compartments. Previously, we showed in vitro biofilms behave as independent compartments impacting the pharmacodynamics. The present study investigated this phenomenon in vivo.

METHODS: Seaweed alginate beads with P. aeruginosa resembling biofilms, either freshly produced (D0) or incubated for 5 days (D5) were installed s.c in BALB/c mice. Mice (n = 64) received tobramycin 40 mg/kg s.c. and were sacrificed at 0.5, 3, 6, 8, 16 or 24 h after treatment. Untreated controls (n = 14) were sacrificed, correspondingly. Tobramycin concentrations were determined in serum, muscle tissue, lung tissue and beads. Quantitative bacteriology was determined.

RESULTS: The tobramycin peak concentrations in serum was 58.3 (±9.2) mg/L, in lungs 7.1 mg/L (±2.3), muscle tissue 2.8 mg/L (±0.5) all after 0.5 h and in D0 beads 19.8 mg/L (±3.5) and in D5 beads 24.8 mg/L (±4.1) (both 3 h). A 1-log killing of P. aeruginosa in beads was obtained at 8h, after which the bacterial level remained stable at 16 h and even increased in D0 beads at 24 h. Using the established diffusion retardation model the free tobramycin concentration inside the beads showed a delayed buildup of 3 h but remained lower than the MIC throughout the 24 h.

CONCLUSIONS: The present in vivo study based on tobramycin exposure supports that biofilms behave as independent pharmacological microcompartments. The study indicates, reducing the biofilm matrix would increase free tobramycin concentrations and improve therapeutic effects.

Original languageEnglish
JournalJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Volume19
Issue number6
Pages (from-to)996-1003
Number of pages8
ISSN1569-1993
DOIs
Publication statusPublished - Nov 2020

ID: 61992860